Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

A global phase 3 trial is evaluating ASP-1929 photoimmunotherapy with Keytruda for recurrent HNSCC, involving around 400 patients. ASP-1929, an antibody-dye conjugate targeting EGFR, is activated by ...

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends to introduce a subcutaneous form of it this year. It's important to also note that Merck is ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Merck & Co.’s Keytruda is the world’s best-selling drug and has been a cancer juggernaut for more than a decade, scoring its 40th indication in June and adding yet another in late September.

Despite the lowered price target from $136 to $119 due to risks related to Keytruda’s loss-of-exclusivity and Medicare price caps, Graybosch remains optimistic about Merck’s ability to shift ...

One of the critical reasons is Merck’s plan to launch its subcutaneous version of Keytruda (pembro) earlier than previously anticipated, with a new target date of 2025. This accelerated timeline ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.